Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.

Wednesday, January 2, 2013

• Phase 3 DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer

  WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar(®) (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary ... read more